1.Overview of the disease: Uterine fibroids are the most common benign tumors in women, with an incidence of 20-25% in women of childbearing age, often multiple and varying in size. According to the location, it can be divided into 3 types: submucosal leiomyoma, intermural leiomyoma and subplasma leiomyoma. Symptoms include excessive menstrual flow or/and non-menstrual bleeding, often complicated by anemia, increased leucorrhea, abdominal mass, lower abdominal cramping or other pelvic pressure symptoms such as frequent urination and bowel problems, and even miscarriage and infertility. In addition, there are still asymptomatic people. 2.Diagnostic points: The preliminary diagnosis can be made according to the medical history and gynecological examination. ultrasound, CT and MRI can clarify the location, size and shape of uterine fibroids, which has the value of localization and qualitative diagnosis, and the correct diagnosis rate can reach more than 95%. 3.Treatment options: Traditional treatment methods include hysterectomy, myomectomy, laparoscopic myomectomy and hormone therapy. In recent years, uterine artery embolization has been used to treat the disease because it has the advantages of less trauma, less side effects, good efficacy (efficiency above 90%), preservation of the uterus and normal fertility. Embolization of uterine fibroids is indicated for patients younger than 58 years of age or for recurrence of fibroids after surgery. Embolization is not indicated for subplasmalemmal fibroids with tissues, pelvic infection or pregnancy. Embolization of uterine fibroids is performed by transcatheter femoral artery puncture and superselective cannulation into the uterine artery. The embolic agent is slowly released under fluoroscopic surveillance until the uterine artery is blocked or the tumor staining disappears. The embolization agent is usually pindamycin-iodine oil emulsifier or PVA pellets. This procedure should be performed 3 to 7 days after menstruation. When the bleeding volume is large, it may not be necessary to perform elective. 4.Complications and treatment: The adverse effects of embolization treatment are varying degrees of lower abdominal pain, soreness and swelling, nausea, vomiting, fever, etc. The incidence is about 11%-80%. After symptomatic treatment, the above symptoms disappear within 1 week. The pain may last for 1 to 4 weeks in individual patients, and a follow-up visit to the doctor should be made to rule out possible complications. Vaginal bleeding may occur in a few patients and is usually small and lasts for 3-4 days, mainly due to ischemia and necrosis of the endometrium. Amenorrhea can occur in patients nearing menopause in age, and a few patients of childbearing age will stop menstruating for 1 to 3 cycles and then return to normal. The incidence of complications is generally less than 5%. Uterine artery embolization does not usually affect the ovarian blood supply and therefore has minimal impact on ovarian function. In addition to the complications of general angiography and embolization, special cases such as diffuse necrosis of the uterus, skin necrosis of the pubic area and buttocks, and necrosis of submucosal myoma dislodged into the uterine cavity combined with uterine cavity infection have been reported, all of which are rare. 5, health care and rehabilitation treatment: postoperative gynecological hygiene should be paid attention to, short-term contraception. Regular outpatient follow-up, and review B-ultrasound, CT or MR 3-6 months after surgery to assess the effect of embolization. Interventional embolization of uterine fibroids is more popular in Europe and the United States. In the late 1990s, interventional embolization of uterine fibroids has been carried out in the interventional department of our hospital. In recent years, this technique has become a routine treatment for uterine fibroids in our hospital, with close cooperation between the Department of Interventional Medicine and the Department of Obstetrics and Gynecology.